Antidotes to non-vitamin K oral anticoagulants: Necessary or not?

Expert Opinion on Pharmacotherapy

Volumn 16, Issue 11, 2015, Pages 1573-1576

  Proietti, Marco ^a,b   Lip, Gregory Y H ^a,c  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c AALBORG UNIVERSITY   (Denmark)

Author keywords

Antidotes; Bleeding risk; Non vitamin K oral anticoagulants; Reversal strategies

Indexed keywords

ANDEXANET ALFA; ANTICOAGULANT AGENT; ANTIDOTE; APIXABAN; DABIGATRAN ETEXILATE; EDOXABAN; IDARUCIZUMAB; NON VITAMIN K ORAL ANTICOAGULANT; RIVAROXABAN; UNCLASSIFIED DRUG; WARFARIN; DABIGATRAN; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; PYRIDONE DERIVATIVE; THIAZOLE DERIVATIVE;

ANTICOAGULATION; ATRIAL FIBRILLATION; BLEEDING; CARDIOVASCULAR RISK; DRUG EFFICACY; DRUG SAFETY; HUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; VENOUS THROMBOEMBOLISM; CHEMICALLY INDUCED; HEMORRHAGE; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ANTICOAGULANTS; ATRIAL FIBRILLATION; DABIGATRAN; HEMORRHAGE; HUMANS; PYRAZOLES; PYRIDINES; PYRIDONES; RIVAROXABAN; THIAZOLES; VENOUS THROMBOEMBOLISM;

EID: 84936966832     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2015.1057119     Document Type: Review

References (20)

1. De Caterina R, Husted S, Wallentin L, et al. Vitamin K antagonists in heart disease: Current status and perspectives (Section III). Thromb Haemost 2013;110(6):1087-107
2. Husted S, de Caterina R, Andreotti F, et al. Non-vitamin K antagonist oral anticoagulants (NOACs): No longer new or novel. Thromb Haemost 2014;111(5):781-2
3. Skjøth F, Larsen TB, Rasmussen LH, Lip GYH. Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation. An indirect comparison analysis. Thromb Haemost 2014;111(5):981-8
4. Hirschl M, Kundi M. New oral anticoagulants in the treatment of acute venous thromboembolism-a systematic review with indirect comparisons. Vasa 2014;43(5):353-64
5. Schulman S. New oral anticoagulant agents-general features and outcomes in subsets of patients. Thromb Haemost 2014;111(4):575-82
6. Glund S, Moschetti V, Norris S, et al. A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran. Thromb Haemost 2015;113(5):943-51
7. Chan NC, Paikin JS, Hirsh J, et al. New oral anticoagulants for stroke prevention in atrial fibrillation: Impact of study design, double counting and unexpected findings on interpretation of study results and conclusions. Thromb Haemost 2014;111:798-807
8. Hart RG, Diener H-C, Yang S, et al. Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial. Stroke 2012;43(6):1511-17
9. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365(10):883-91
10. Hylek EM, Held C, Alexander JH, et al. Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE trial (Apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation): Predictors, characteristics, and clinical outcomes. J Am Coll Cardiol 2014;63:2141-7
11. Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013;369:2093-104
12. Sardar P, Chatterjee S, Lavie CJ, et al. Risk of major bleeding in different indications for new oral anticoagulants: insights from a meta-analysis of approved dosages from 50 randomized trials. Int J Cardiol 2015;179:279-87
13. Greinacher A, Thiele T, Selleng K. Reversal of anticoagulants: an overview of current developments. Thromb Haemost 2015;113(5):931-42
14. Wang X, Mondal S, Wang J, et al. Effect of activated charcoal on apixaban pharmacokinetics in healthy subjects. Am J Cardiovasc Drugs 2014;14(2):147-54
15. Khadzhynov D, Wagner F, Formella S, et al. Effective elimination of dabigatran by haemodialysis. A phase I single-centre study in patients with end-stage renal disease. Thromb Haemost 2013;109(4):596-605
16. Gomez-Outes A, Suarez-Gea ML, Lecumberri R, et al. Specific antidotes in development for reversal of novel anticoagulants: a review. Recent Pat Cardiovasc Drug Discov 2014;9(1):2-10
17. Schiele F, van Ryn J, Canada K, et al. A specific antidote for dabigatran: functional and structural characterization. Blood 2013;121(18):3554-62
18. Lu G, DeGuzman FR, Hollenbach SJ, et al. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med 2013;19(4):446-51
19. Siegal DM. Managing target-specific oral anticoagulant associated bleeding including an update on pharmacological reversal agents. J Thromb Thrombolysis 2015;39(3):395-402
20. Late-Breaking Clinical Trial Abstracts. Circulation 2014;130(23):2105-26